Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 48 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/26/2005 First Published: 4/23/2003


1.		Phase II/III Randomized Study of CC-5013 in Patients With Progressive or Relapsed Metastatic Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0210051 CELGENE-CDC-501-MEL-001, MSKCC-03026, NCT00060281

Last Modified: 6/13/2008 First Published: 6/23/2003


2.		Phase III Randomized Study of Dexamethasone With or Without Lenalidomide in Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				SWOG-S0232 S0232, NCT00064038


3.		Study to Compare the Efficacy and Safety of CC-5013 Vs. Placebo in Subjects With Metastatic Malignant Melanoma.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				CC-5013-MEL-002 NCT00057616


4.		Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Other				UARK 2003-35 NCT00093028

Last Modified: 7/21/2008 First Published: 11/22/2004


5.		Phase III Randomized Study of Lenalidomide With Standard-Dose Versus Low-Dose Dexamethasone With or Without Salvage Therapy Comprising Thalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				ECOG-E4A03 E4A03, NCT00098475


6.		Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q- Abnormality

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CC-5013-MDS-004 NCT00179621


7.		A Multicentre, Single-Arm, Open-Label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CC-5013-MM-018 NCT00420849


8.		CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				CC-5013-MM-009 NCT00056160


9.		A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				Not specified				Pharmaceutical / Industry				CC-5013-MM-010 NCT00424047


10.		Study of Lenalidomide With Topotecan In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				CC-5013-OVRY-002 NCT00179712

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute